Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
 Aug 14, 2024 
 Sarah Boyce, CEO of Avidity Biosciences, shares her inspiring journey from Liverpool to leading a company focusing on RNA medicines for rare muscle diseases. She discusses the innovative therapies being developed for conditions like myotonic dystrophy and Duchenne muscular dystrophy. The conversation dives into the challenges of transitioning to a CEO role and the significance of emotional intelligence in leadership. Boyce also highlights advancements in RNA therapeutics, including promising drug trials and the importance of community engagement in biotechnology. 
 Chapters 
 Transcript 
 Episode notes 
 1  2  3  4  5  6  7  8 
 Intro 
 00:00 • 2min 
 A Journey from Liverpool: Childhood and Early Influences 
 02:20 • 3min 
 From Challenges to Careers 
 05:33 • 7min 
 From Intern to Industry Leader 
 12:25 • 16min 
 Innovations in RNA Delivery 
 28:39 • 7min 
 Navigating Leadership Transitions in Biotechnology 
 35:56 • 2min 
 Transforming RNA Therapeutics 
 38:15 • 9min 
 Advancements in RNA Medicine for Muscle Diseases 
 47:09 • 21min 
